This is a great example of how modern anticoagulation has evolved from a relatively blunt approach into increasingly individualized risk management. The central challenge is always balancing two competing risks: preventing thromboembolism while minimizing clinically significant bleeding.
As a physician-scientist, I think the most important shift is moving beyond the idea that there is one “best” anticoagulant for everyone. The right choice depends on the indication, kidney and liver function, age, comorbidities, drug interactions, adherence, procedural plans, and critically, the patient’s individual risk of both thrombosis and bleeding.
What makes this field particularly interesting is how rapidly the evidence continues to evolve. Newer agents and reversal strategies have expanded our options, while better risk stratification and monitoring may allow us to tailor treatment more precisely.
The only major trial to test aspirin against Apixaban was the Averroes trial, this trial used the less effective aspirin type (enteric coated) and also allowed the regular use of Ibuprofen. 1, The 2006 Dermot Cox back to back aspirin reversal study showed the enteric coating made aspirins Cox-1 inhibition less effective, also in 2007 the FDA gave out a warning with regard to the use of Ibuprofen with uncoated aspirin with regard to the critical timing of Ibuprofen when used with uncoated aspirin. When using enteric coated aspirin the aspirin release is unpredictable which means Ibuprofen should never be used with enteric coated aspirin. Recent FDA Warning of the Concomitant Use of Aspirin and Ibuprofen and the Effects on Platelet Aggregation https://doi.org/10.1111/j.1520-037X.2007.06496.x The aspirin type and the concomitant use of Ibuprofen appear in the Protocol of Averroes but NOT in the trial. Apixaban had 3 drugs banned. Aspirin had none banned.
This is a great example of how modern anticoagulation has evolved from a relatively blunt approach into increasingly individualized risk management. The central challenge is always balancing two competing risks: preventing thromboembolism while minimizing clinically significant bleeding.
As a physician-scientist, I think the most important shift is moving beyond the idea that there is one “best” anticoagulant for everyone. The right choice depends on the indication, kidney and liver function, age, comorbidities, drug interactions, adherence, procedural plans, and critically, the patient’s individual risk of both thrombosis and bleeding.
What makes this field particularly interesting is how rapidly the evidence continues to evolve. Newer agents and reversal strategies have expanded our options, while better risk stratification and monitoring may allow us to tailor treatment more precisely.
Thank you!
Thank you.
The only major trial to test aspirin against Apixaban was the Averroes trial, this trial used the less effective aspirin type (enteric coated) and also allowed the regular use of Ibuprofen. 1, The 2006 Dermot Cox back to back aspirin reversal study showed the enteric coating made aspirins Cox-1 inhibition less effective, also in 2007 the FDA gave out a warning with regard to the use of Ibuprofen with uncoated aspirin with regard to the critical timing of Ibuprofen when used with uncoated aspirin. When using enteric coated aspirin the aspirin release is unpredictable which means Ibuprofen should never be used with enteric coated aspirin. Recent FDA Warning of the Concomitant Use of Aspirin and Ibuprofen and the Effects on Platelet Aggregation https://doi.org/10.1111/j.1520-037X.2007.06496.x The aspirin type and the concomitant use of Ibuprofen appear in the Protocol of Averroes but NOT in the trial. Apixaban had 3 drugs banned. Aspirin had none banned.
So Insightful! Thank you